Petros Pharmaceuticals (NASDAQ:PTPI) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head to Head Review

Risk & Volatility

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.

Institutional & Insider Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Calliditas Therapeutics AB (publ) and Petros Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62
Petros Pharmaceuticals	$5.11 million	0.05	-$8.16 million	($39.69)	0.00

Petros Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Petros Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

Petros Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 7 of the 11 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.